Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 321 participants.
Also called NCT01982292
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking
- Phase
- Phase 2
- Enrolled
- 321 participants
- Sponsor
- Registry
-
NCT01982292 -
2013-002781-39
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Czechia, Finland, Germany, Italy, Netherlands, Norway, Romania, Russia, Spain, Sweden, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT01982292. Randomized; quadruple masking. Start 2014-05 (registry gives no type); primary completion 2015-09 (actual). Results posted on 2016-11-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure
- Acronym
- RELAX-REPEAT
- Condition
- Chronic Heart Failure
- Intervention (Drug)
- RLX030 (serelaxin)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01982292- Content hash
09d767826c738fe4738d8429e8d1ccc5970c85f7bb87bfd33fa503b3209e58d3